Skip to main content

Advertisement

Table 1 The summary of clinical information for 21 Chinese HCC patients

From: HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma

Patient Recurrent with 24 months± Sex Age Primary tumor grade Child BCLC Primary tumor size (cm) Criteria (Milan = 1; UCSF = 2; Exceed = 3) AFP (ng/mL) MELD Time of recurrent after OLT (month) Recurrent tumor organ HBV (pre-OLT) HBV (post-OLT) MULT± SAT± ENCAP± CIRR± VES± THROMB±
HCC1* 1 M 48 III A A3 5*5*3 1 2935.9 8 8 Liver Positive Negative 0 0 0 1 0 1
HCC4* 1 M 59 II A B 8*6*5.5 3 2.5 5 6.5 Liver Positive Positive 1 1 1 0 0 0
HCC5* 1 M 67 II A B 5*4*3 1 >3000 2 18 Liver Negative Negative 1 0 0 1 0 1
HCC11* 1 F 57 II–III A B 0.5–2.5 1 1581.6 2 16 Lung Negative Negative 1 0 0 1 0 0
HCC2 1 M 43 II A B 9*8*6 3 1461.1 21 19 Liver Positive Negative 0 1 N/A 1 0 0
HCC3 1 M 42 III B B 6*6*2.5, 10*8*4 3 >3000 5 14.5 Liver Positive Negative 1 0 0 1 0 1
HCC6 1 M 41 III A B 7*5*4 3 126 4 1.5 Lung Positive Negative 0 0 0 1 0 0
HCC8 1 M 42 III A B 10*10*7 3 >3000 5 11 Liver Positive Negative 0 1 0 1 N/A 1
HCC10 1 M 59 III A A3 4*3.5*3.5 1 1888.2 15 6 Liver Positive Negative 0 0 0 1 0 1
HCC-C2 0 M 55 I–II C D 5.5*5*4.5* 2 5.2 4 N/A N/A Positive Negative 0 0 0 1 0 0
HCC-C6 0 M 51 II B A3 3*2.5*2* 1 137.5 13 N/A N/A Positive Negative 0 0 0 1 0 0
HCC-C8 0 M 64 I B A3 5*1.5*1.5*, 3*2*2* 3 62.5 13 N/A N/A Positive Positive 1 0 0 1 0 0
HCC-C9 0 M 40 II B A3 1*1*1* 1 9.2 3 N/A N/A Positive N/A 0 0 0 1 0 0
HCC-C11 0 M 62 I A A3 3*3*2* 1 5.4 9 N/A N/A Positive Negative 0 0 0 1 0 0
HCC-C12 0 M 40 II–III A A2 2.5*1.5*1* 1 210.8 4 N/A N/A Positive Positive 0 0 0 1 0 0
HCC-C13 0 M 49 I–II A C 3*2.5*2.5*; 2*2*2* 1 4.3 4 N/A N/A Positive Negative 1 0 0 1 1 0
HCC-C14 0 M 59 II B B 7*5*5* 3 240.7 20 N/A N/A Positive N/A 0 0 0 1 0 0
HCC-C15 0 M 49 II A B 5*4*2*; 5*4.5*3* 3 NA 4 N/A N/A Positive Negative 0 1 0 1 0 0
HCC-C16 0 M 49 II–III B A3 5*5*4* 1 128.9 11 N/A N/A Positive N/A 0 1 0 1 0 0
HCC-C18 0 M 57 I A A2 5*4*4* 1 6.6 2 N/A N/A Positive Negative 0 0 0 1 0 0
HCC-C19 0 M 41 II–III A B 4*2.5*2*, 3*2*1.8* 2 220.9 2 N/A N/A Positive Positive 1 0 0 1 0 0
  1. Patient OLT inclusion criteria included: ECOG (Eastern Cooperative Oncology Group performance status) score 0–2, tumor within Hangzhou criteria and no major vascular invasion or extra hepatic metastases from imaging studies. Exclusion criteria included absolute contradictions of: involvement of the surrounding tissue or distant metastasis, co-current non-curable extra hepatic malignancies, active infection; relative contraindications included: pulmonary hypertension, symptomatic ischemic heart disease, severe renal insufficiency, and mental disorders
  2. AFP alpha-fetoprotein, HBV hepatitis B virus, MULT multiplicity, ENCAP encapsulated, CIRR cirrhosis, THROMB thrombosis, OLT orthotopic liver transplantation, BCLC barcelona Clinical Liver Cancer staging, SAT satellite, VES vessel, Child Child-Pugh score, MELD Model for End-Stage Liver Disease, ±1 Yes, 0 No
  3. * These 4 patients have matched primary and recurrent tumor specimens, normal adjacent tissue from the primary and recurrent tumors, and recipient blood specimens (n = 20 total specimens)
  4. Italicized rows indicate patients who did not experience tumor recurrence post-OLT (n = 12), while non-italicized rows indicate patients who did experience tumor recurrence post-OLT (n = 9)